Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-22), Jazz Pharmaceuticals's 3-1 Month Momentum % is 11.98%.
The industry rank for Jazz Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
FRA:J7Z's 3-1 Month Momentum % is ranked better than 71.29% of 1383
companies
in the Biotechnology industry
Industry Median: 0.47
vs FRA:J7Z: 11.98
Jazz Pharmaceuticals (FRA:J7Z) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Jazz Pharmaceuticals 3-1 Month Momentum % Related Terms
FRA:J7Z vs ASND, BBIO, EXEL: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's 3-1 Month Momentum % falls into.
Jazz Pharmaceuticals (FRA:J7Z) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals (FRA:J7Z) has a 3-1 Month Momentum % of 11.98% as of Sep. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Jazz Pharmaceuticals and its competitors. According to the industry distribution chart, Jazz Pharmaceuticals ranks #397 out of 1383 companies in the Biotechnology industry, placing it in the top 28.7%.
Is Jazz Pharmaceuticals' 3-1 Month Momentum % too high?
Jazz Pharmaceuticals' current 3-1 Month Momentum % is 11.98%. The Biotechnology industry median 3-1 Month Momentum % is 0.47. Jazz Pharmaceuticals' value of 11.98% is 2448.9% above this industry median. Based on the distribution chart, Jazz Pharmaceuticals ranks #397 out of 1383 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jazz Pharmaceuticals has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' 3-1 Month Momentum % compare to ASND and BBIO?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #397 out of 1383 companies for 3-1 Month Momentum %. This puts Jazz Pharmaceuticals in the upper half of its industry. The industry median 3-1 Month Momentum % is 0.47. Jazz Pharmaceuticals' value of 11.98% is 2448.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 0.47, based on 1,383 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jazz Pharmaceuticals's current 3-1 Month Momentum % of 11.98% is 2448.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Jazz Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 0.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jazz Pharmaceuticals's current 3-1 Month Momentum % is 11.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (FRA:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €130.02, compared to a current price of €210.00 — trading 61.5% above its estimated fair value. The current 3-1 Month Momentum % is 11.98% and 2448.9% above the Biotechnology industry median of 0.47. Jazz Pharmaceuticals' overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Jazz Pharmaceuticals (FRA:J7Z), the current 3-1 Month Momentum % is 11.98% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (FRA:J7Z) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of €210.00 is trading 61.5% above its estimated GF Value™ of €130.02.
GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:J7Z:
3-1 Month Momentum %: 11.98%
GF Value™: €130.02 vs. price of €210.00 (61.5% above fair value)
Industry Position: 2448.9% above the Biotechnology median (#397 of 1383)
No single metric tells the full story. See the FRA:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
74GF Score
Get the complete analysis for FRA:J7Z
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J7Z has been successfully added to your 
